Serum Levels of Endostatin, an Angiogenesis Inhibitor, in Patients With Benign and Malignant Lesions of the Breast (original) (raw)

Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal Women

Garnet Anderson

American Journal of Epidemiology, 2008

View PDFchevron_right

Endometriosis-associated Malignancy

Dietmar Schmidt

Geburtshilfe Und Frauenheilkunde, 2016

View PDFchevron_right

Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast

Gerardo Iacopino

Histopathology, 2000

View PDFchevron_right

Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women's Health Initiative Observational Study

Jean Wactawski-wende

Breast Diseases: A Year Book Quarterly, 2013

View PDFchevron_right

Tamoxifen and fenretinide in women with metastatic breast cancer

Maria Merino

Breast Cancer Research and Treatment, 1999

View PDFchevron_right

Angiogenesis and Vasculogenesis in Health and Disease

Alessio D'Alessio

BioMed Research International, 2015

View PDFchevron_right

Prognostic Significance of Complete Blood Count in Breast Cancer Patients

Preeti Beniwal

2016

View PDFchevron_right

Stimulation of Human Breast Cancer in Vivo

Claudio Lanfranco

Annals of the New York Academy of Sciences, 1993

View PDFchevron_right

Aromatase inhibitors in breast cancer

Manisha Kotadiya, jaydeep savaliya

The American Journal of Geriatric Pharmacotherapy, 2004

View PDFchevron_right

High serum follistatin levels in women with ovarian endometriosis

Marco Franchini

Fertility and Sterility, 2007

View PDFchevron_right

Risk Factors Leading to High Prevalence of Breast Cancer

Noor Fatima

Journal of Applied Pharmacy, 2013

View PDFchevron_right

Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome

Didier Wion, Christine Ménétrier-caux

British journal of cancer, 2006

View PDFchevron_right

Centered on Breast Cancer

Luz Claudio

Environmental Health Perspectives, 2007

View PDFchevron_right

Breast Cancer in Older Women

Helen Gogas

Journal of the American Geriatrics Society, 2001

View PDFchevron_right

Cardiovascular Dysautonomia in Patients with Breast Cancer

Vera Geraldes

The Open Cardiovascular Medicine Journal, 2022

View PDFchevron_right

Angiogenesis, p53, and c‐erbB‐2 immunoreactivity and clinicopathological features in male breast cancer

Yonit Bomstein

Journal of Surgical Oncology, 2000

View PDFchevron_right

Second consensus on medical treatment of metastatic breast cancer

L. Petruzelka

Annals of Oncology, 2006

View PDFchevron_right

Association of breast cancer with meningioma

Christos Markopoulos

European Journal of Surgical Oncology (EJSO), 1998

View PDFchevron_right

The Next Steps for Endocrine Pathology

Sylvia L Asa

Endocrine Pathology, 2022

View PDFchevron_right

Systemic Therapy of Metastatic Breast Cancer

Carsten Rose

Acta Oncologica, 1990

View PDFchevron_right

Data from Prediction of Distant Recurrence Using EndoPredict Among Women with ER<sup>+</sup>, HER2<sup>−</sup> Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only

Zsuzsanna Bago-horvath

2023

View PDFchevron_right

Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer

Fred C. G. J. Sweep

Oncogene, 2003

View PDFchevron_right

Angiopoietins in Human Breast Milk

TANER OZGURTAS

Breastfeeding Medicine, 2016

View PDFchevron_right

Cyclin D1, Id1 and EMT in breast cancer

Andrew Sims

BMC cancer, 2011

View PDFchevron_right

Blood-Based Biomarkers of Early-Onset Breast Cancer

Nasim Ahmadiyeh

2014

View PDFchevron_right